Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers

Página do item simplificado
dc.contributor.authorSader, Helio Silva [UNIFESP]
dc.contributor.authorWatters, A. A.
dc.contributor.authorFritsche, T. R.
dc.contributor.authorJones, R. N.
dc.contributor.institutionJMI Labs
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionTufts Univ
dc.date.accessioned2018-06-15T17:53:10Z
dc.date.available2018-06-15T17:53:10Z
dc.date.issued2008-02-01
dc.description.abstractDaptomycin is a cyclic lipopeptide with potent bactericidal activity against Gram-positive organisms and has been approved by the United States Food and Drug Administration for the treatment of Staphylococcus aureus bacteremia and infectious endocarditis (right-side). We evaluated the activity of daptomycin against bloodstream infection S. aureus strains from 4,799 patients hospitalized in 32 medical centers (12 European countries, Turkey and Israel) with bloodstream infections (BSI) during a 5-year period (2002-2006). Intravenous catheters were the source of infection in 15% of cases, and those strains were analyzed separately. All strains were susceptibility tested by reference broth microdilution methods utilizing calcium supplementation (50 mg/L) when testing daptomycin. Bactericidal activity of daptomycin and vancomycin were evaluated against a subset of 50 randomly selected strains. Daptomycin (MIC (50/90), 0.25/0.5 mg/L), vancomycin (MIC50/90, 1/1 mg/L), and linezolid (MIC50/90, 2/2 mg/L), were highly active (>99.9% susceptibility) against the strains evaluated; and daptomycin was the most potent (lowest MIC90) among these compounds. Resistance rates to oxacillin and levofloxacin were generally elevated, especially when an intravenous catheter was the source of infection.en
dc.description.affiliationJMI Labs, N Liberty, IA 52317 USA
dc.description.affiliationUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent28-32
dc.identifier.citationJournal Of Chemotherapy. Florence: Esift Srl, v. 20, n. 1, p. 28-32, 2008.
dc.identifier.issn1120-009X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/44240
dc.identifier.wosWOS:000254066100003
dc.language.isoeng
dc.publisherEsift Srl
dc.relation.ispartofJournal Of Chemotherapy
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectdaptomycinen
dc.subjectvancomycinen
dc.subjectlinezoliden
dc.subjectoxacillinen
dc.subjectlevofloxacinen
dc.subjectbacteremiaen
dc.subjectendocarditisen
dc.titleActivity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centersen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos